Food and Drug Administration (FDA)
NEWS
Ultragenyx Pharmaceutical Inc. and GeneTx Biotherapeutics LLC announced a partnership to develop GeneTx’s GTX-102, an antisense oligonucleotide (ASO) for the treatment of Angelman syndrome, a serious, debilitating, rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide.
Akari Therapeutics, Plc announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients.
The new designation granted to Calquence marks the 10th such designation the company has earned since 2014, AstraZeneca said.
The Democratic senators called it “unconscionable” that AveXis and its parent company Novartis would include manipulated data in order to rush a product to market.
Now that July has come and gone, the U.S. Food and Drug Administration is back to work approving drugs. This week marks three PDUFA target action dates, although one has already been rejected and another hit a snag that doesn’t appear to affect the decision date.
Before it finalizes the guidance, the FDA is seeking comment from drugmakers about the proposed plans.
Myriad Genetics, Inc. announced that the AstraZeneca/Merck Phase III PROfound studydemonstrated that men with metastatic castration-resistant prostate cancer who tested positive for germline and somatic mutations in homologous recombination repair genes benefitted from treatment with Lynparza®, a novel PARP inhibitor.
Former Touch Bionics CEO joins Adapttech as company secures FDA decision for medical device that improves prosthesis fit
Quanta Dialysis Technologies Ltd, a British medical technology company developing a personal haemodialysis system for patient use in the clinic and the home, announces that it has begun human factors testing of SC+ in the United States with Design Science, a leading specialist in medical device usability.
JOBS
IN THE PRESS